Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Liraglutide with Two Pen-injectors
NCT02207348Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2014
- Primary completion
- Sep 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liraglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the plasma concentration-time curve and Maximum observed plasma concentration. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02207348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207348.